75. クッシング病 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 225 / 薬物数 : 167 - (DrugBank : 49) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 144

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
11-ß-hydroxysteroid dehydrogenase type 1
   Sparrow Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-006184-19-RO   Bulgaria;Romania;United States
      2022   Phase 2   EUCTR2021-006184-19-BG   Bulgaria;Romania;United States
11C-methionine PET/CT
   Imperial College London
      2024   -   NCT06701838   -
17ß-hydroxy-11ß-(4-dimethylaminophenyl)17A-(PROP-1-ynyl)estra-4,9-DIEN-3-ONE
   Laboratoire HRA Pharma
      2007   -   EUCTR2006-004679-36-NL   France;Germany;Italy;Netherlands
      2007   -   EUCTR2006-004679-36-DE   France;Germany;Italy;Netherlands;United States
      2006   -   EUCTR2006-004679-36-FR   France;Germany;Italy;Netherlands
18F-dopa
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1999   Phase 1/Phase 2   NCT00001849   United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 2   NCT02019706   United States
1H-pyrazol
   CORCEPT THERAPEUTICS
      2019   Phase 3   EUCTR2018-003096-35-IT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
   Corcept Therapeutics Incorporated
      2022   Phase 2;Phase 3   EUCTR2018-001616-30-NL   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 3   EUCTR2018-003096-35-RO   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 2;Phase 3   EUCTR2018-001616-30-RO   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-ES   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-DE   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-BG   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-PL   Austria;Bulgaria;Canada;Colombia;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-NL   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-ES   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-DE   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-BG   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-AT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 2   EUCTR2018-001616-30-HU   Bulgaria;Germany;Hungary;Italy;Netherlands;Romania;Spain;United States
24-hour urine test
   Centre Hospitalier Universitaire de Nimes
      2019   -   NCT03974789   France
2S,4R-(-)-ketoconazole
   Cortendo AB
      2016   Phase 3   EUCTR2013-002133-37-CZ   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-IT   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-ES   Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Serbia;Spain;Sweden;United Kingdom;United States
2S,4R-(-)-ketoconazole, levoketoconazole
   Cortendo AB
      2016   Phase 3   EUCTR2013-002133-37-HU   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002133-37-DK   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002133-37-DE   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002133-37-BG   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-SE   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;United Kingdom
      2014   Phase 3   EUCTR2013-002133-37-NL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-BE   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
68GA-dotatate
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 2   NCT02019706   United States
Abiraterone acetate
   Azienda Ospedaliera Spedali Civili di Brescia
      2017   Phase 2   NCT03145285   Italy
Abiraterone acetato
   AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
      2016   Phase 2   EUCTR2016-000945-29-IT   Italy
Acthrel
   National Institute of Neurological Disorders and Stroke (NINDS)
      2025   -   NCT04569591   United States
      2011   Early Phase 1   NCT01459237   United States
Adrenal aldosterone synthase (CYP11b2) staining
   Helsinki University Central Hospital
      2022   -   NCT05446779   Finland
Adrenal cortisol synthase (CYP11b1) staining
   Helsinki University Central Hospital
      2022   -   NCT05446779   Finland
Alprazolam
   Asari Yuko
      2022   Phase 2   JPRN-jRCT1021210011   -
ATR-101
   Millendo Therapeutics US, Inc.
      2017   Phase 2   NCT03053271   United Kingdom;United States
   Millendo Therapeutics, Inc.
      2017   Phase 2   EUCTR2016-002240-17-GB   United Kingdom;United States
Atumelnant
   Crinetics Pharmaceuticals Inc.
      2023   Phase 1/Phase 2   NCT05804669   United States
AZD4017
   University of Oxford, Clinical Trials and Research Governance
      2017   Phase 2   EUCTR2016-003060-40-GB   United Kingdom
AZD4017 and prednisolone
   University of Oxford
      2017   Phase 2   NCT03111810   United Kingdom
Bexarotene
   University of Virginia
      2008   Phase 1/Phase 2   NCT00845351   United States
Cabergolina
   Dipartimento di Medicina-DIMED, università di Padova
      2021   Phase 2   EUCTR2019-004019-29-IT   Italy
Cabergoline
   Erasmus MC
      2011   -   EUCTR2011-003264-77-NL   Netherlands
      2007   -   EUCTR2006-004080-55-NL   Netherlands
   NOVARTIS FARMA S.p.A.
      2014   Phase 2   EUCTR2013-002170-49-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica , S.A.
      2013   Phase 2   EUCTR2013-002170-49-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2013-002170-49-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2013   Phase 2   EUCTR2013-002170-49-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
   RECORDATI GROUP
      2013   Phase 4   NCT01794793   Argentina;Belgium;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;Thailand;Turkey;United States
   Seth Gordhandas Sunderdas Medical College
      2007   Phase 3   NCT00889525   India
   Swedish Pituitary Study group
      2010   -   EUCTR2010-018720-12-SE   Sweden
Cabergoline teva
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2013-002170-49-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
Calcium carbonate
   Pierre Fabre Médicament
      2008   Phase 3   EUCTR2008-002280-14-FR   France
CI-984
   Millendo Therapeutics, Inc.
      2017   Phase 2   EUCTR2016-002240-17-GB   United Kingdom;United States
Cialis - 20 MG 2 compresse rivestite CON film IN blister USO orale
   UMBERTO I - POLICLINICO DI ROMA
      2016   Phase 2   EUCTR2015-004497-15-IT   Italy
Continuous glucose monitoring
   Huashan Hospital
      2014   -   NCT02574793   China
COR-003
   CORTENDO AB
      2018   Phase 3   EUCTR2017-001219-35-IT   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
   Cortendo AB
      2020   Phase 3   EUCTR2017-004647-20-RO   Bulgaria;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-NL   Bulgaria;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-IT   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-004647-20-GR   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-ES   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-004647-20-BG   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-004647-20-HU   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2018   Phase 3   EUCTR2017-001219-35-PL   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-NL   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-HU   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-GR   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-FR   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-ES   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-DK   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-BG   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2016   Phase 3   EUCTR2013-002133-37-HU   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2013-002133-37-CZ   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002133-37-DK   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002133-37-DE   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002133-37-BG   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-SE   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;United Kingdom
      2014   Phase 3   EUCTR2013-002133-37-NL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-IT   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-ES   Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Serbia;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002133-37-BE   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Cormeto - 250 MG capsule molli 50 capsule IN flacone hdpe
   AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
      2019   Phase 4   EUCTR2019-002008-41-IT   Italy
CORT125134
   CORCEPT THERAPEUTICS
      2019   Phase 3   EUCTR2018-003096-35-IT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 2   EUCTR2018-001616-30-IT   Bulgaria;Germany;Hungary;Italy;Netherlands;Romania;Spain;United States
      2016   Phase 2   EUCTR2016-000899-23-IT   Hungary;Italy;Netherlands;United Kingdom
   Corcept Therapeutics
      2016   Phase 2   NCT02804750   Hungary;Italy;Netherlands;United Kingdom;United States
   Corcept Therapeutics Incorporated
      2022   Phase 2;Phase 3   EUCTR2018-001616-30-NL   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 3   EUCTR2018-003096-35-RO   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 2;Phase 3   EUCTR2018-001616-30-RO   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-ES   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-DE   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-BG   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-PL   Austria;Bulgaria;Canada;Colombia;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-NL   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-ES   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-DE   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-BG   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-AT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 2   EUCTR2018-001616-30-HU   Bulgaria;Germany;Hungary;Italy;Netherlands;Romania;Spain;United States
      2016   Phase 2   EUCTR2016-000899-23-NL   Hungary;Netherlands;United Kingdom;United States
      2016   Phase 2   EUCTR2016-000899-23-HU   Hungary;Netherlands;United Kingdom;United States
      2016   Phase 2   EUCTR2016-000899-23-GB   Hungary;Netherlands;United Kingdom;United States
Corticotropin-releasing hormone
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1982   -   NCT00001180   United States
CT scan
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 2   NCT02019706   United States
Cushing'S syndrome confirmation
   Corcept Therapeutics
      2009   -   NCT00796783   United States
Cyclo ((diaminoethyl-carbamate)hypro-PHG-(D) TRP-LY DI-aspartate
   Novartis Pharma Services AG
      2007   -   EUCTR2006-004111-22-FR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
Cyclo ((diaminoethyl-carbamate)hypro-PHG-(D)TRP-LY DI-aspartate
   Novartis Pharma Services AG
      2007   -   EUCTR2006-004111-22-FR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
Cyclo((diaminoethyl-carbamate)hypro-PHG-(D)TRP-LYS-TYR(BZL)-PHE) DI-aspartate
   Novartis Farmaceútica S.A.
      2007   -   EUCTR2006-004111-22-ES   Argentina;Belgium;Brazil;Canada;China;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Poland;Portugal;Spain;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2008   -   EUCTR2006-004111-22-HU   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2008   Phase 3   EUCTR2006-004111-22-GB   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-PT   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-GR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FI   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-DK   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-DE   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-004111-22-BE   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
Dabigatran etexilate
   Corcept Therapeutics
      2022   Phase 1   NCT05347979   United States
Ddavp
   Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine
      2015   -   JPRN-UMIN000018891   Japan
   Kageyama Kazunori
      2018   Phase 3   JPRN-jRCTs021180039   -
   Peking Union Medical College Hospital
      2023   -   ChiCTR2400094170   China
Denosumab
   Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2024   -   ChiCTR2400091528   China
Desmopressin
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2024   Phase 2   NCT06635629   United States
Dexamethasone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2024   Phase 2   NCT06635629   United States
Dexamethasone suppression test
   Marmara University
      2020   -   NCT05568602   Turkey
Dexamethasone test
   Centre Hospitalier Universitaire de Nimes
      2019   -   NCT03974789   France
Dostinex
   ASSOCIAZIONE ITALIANA ENDOCRINOLOGIA-METABOLISMO-IPOFISI
      2006   -   EUCTR2006-005218-11-IT   Italy
   Dipartimento di Medicina-DIMED, università di Padova
      2021   Phase 2   EUCTR2019-004019-29-IT   Italy
   Erasmus MC
      2007   -   EUCTR2006-004080-55-NL   Netherlands
   NOVARTIS FARMA S.p.A.
      2014   Phase 2   EUCTR2013-002170-49-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica , S.A.
      2013   Phase 2   EUCTR2013-002170-49-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2013-002170-49-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2013   Phase 2   EUCTR2013-002170-49-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
Dotatate PET-CT
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 2   NCT02019706   United States
Eplerenone
   Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus
      2009   -   JPRN-UMIN000002925   Japan
F-dopa PET CT
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 2   NCT02019706   United States
F18ceto
   Uppsala University
      2019   Early Phase 1   NCT05361083   Sweden
Fimepinostat
   University of California, Los Angeles
      2025   Phase 2   NCT05971758   United States
Gated MRI scan
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 2   NCT02019706   United States
Gefitinib
   Huashan Hospital
      2015   Phase 2   NCT02484755   China
Genotropin 12MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Genotropin 5.3MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Genotropin miniquick 0.2MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Genotropin miniquick 0.4MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Genotropin miniquick 0.6MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Genotropin miniquick 0.8MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Genotropin miniquick 1.0MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Genotropin miniquick 1.2MG
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
Glucocorticoids
   University of Leeds
      1998   -   NCT03575247   -
Histopathological analysis
   Helsinki University Central Hospital
      2022   -   NCT05446779   Finland
HRA052015
   Laboratoire HRA Pharma
      2007   -   EUCTR2006-004679-36-NL   France;Germany;Italy;Netherlands
      2007   -   EUCTR2006-004679-36-DE   France;Germany;Italy;Netherlands;United States
      2006   -   EUCTR2006-004679-36-FR   France;Germany;Italy;Netherlands
   Sheffield Teaching Hospitals NHS Foundation Trust
      2009   Phase 2   EUCTR2007-007604-15-GB   United Kingdom
Hydrocortisone
   Tianjin Medical University General Hospital
      2014   -   JPRN-UMIN000041513   Asia(except Japan)
   University Hospital, Bordeaux
      2012   -   NCT02889224   France
Hypercortisolism
   University Hospital, Bordeaux
      2012   -   NCT02889224   France
Insulin
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
Intervention/treatment
   Centre hospitalier de l'Université de Montréal (CHUM)
      2023   Phase 4   NCT06131580   Canada
IPC
   Huashan Hospital
      2020   -   NCT04486859   China
Isturisa
   RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
      2019   Phase 2   EUCTR2018-001522-25-BE   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
   Recordati AG
      2023   Phase 2   EUCTR2018-001522-25-FR   Belgium;Bulgaria;France;Israel;Italy;Slovenia;Spain;United Kingdom;United States
Ketoconazole
   Erasmus MC
      2011   -   EUCTR2011-003264-77-NL   Netherlands
      2007   -   EUCTR2006-004080-55-NL   Netherlands
L0006cp03A
   Pierre Fabre Médicament
      2008   Phase 3   EUCTR2008-002280-14-FR   France
Lapatinib
   Peking Union Medical College Hospital
      2017   -   ChiCTR-OPC-17011664   China
LCI699
   NOVARTIS FARMA
      2011   Phase 2   EUCTR2010-022403-22-IT   Italy;United States
   NOVARTIS FARMA S.p.A.
      2014   Phase 3   EUCTR2013-004766-34-IT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Slovakia;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-002840-34-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A
      2018   Phase 2   EUCTR2017-002840-34-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-001522-25-ES   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-004092-23-ES   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2014   Phase 3   EUCTR2013-004766-34-ES   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Slovakia;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2020   Phase 2   EUCTR2018-001522-25-IT   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-FR   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2014-004092-23-PT   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-PL   Belgium;Brazil;Canada;China;Costa Rica;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-GR   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-BE   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2015   Phase 3   EUCTR2013-004766-34-NL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-FR   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-AT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2014   Phase 3   NCT02180217   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 2   NCT01331239   France;Italy;Japan;United States
   RECORDATI GROUP
      2021   Phase 2   NCT03708900   Belgium;Bulgaria;France;Italy;Slovenia;United Kingdom;United States
   RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
      2019   Phase 2   EUCTR2018-001522-25-BE   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
   Recordati AG
      2023   Phase 2   EUCTR2018-001522-25-FR   Belgium;Bulgaria;France;Israel;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-SI   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-GB   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-BG   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-NL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2019   Phase 2   EUCTR2017-002840-34-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002840-34-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2018   Phase 2   EUCTR2017-002840-34-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      -   Phase 2   EUCTR2017-002840-34-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
LCI699, 1 MG
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
LCI699, 10 MG
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
LCI699, 20 MG
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
LCI699, 5 MG
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
Levoketoconazole
   CORTENDO AB
      2018   Phase 3   EUCTR2017-001219-35-IT   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
   Cortendo AB
      2020   Phase 3   EUCTR2017-004647-20-RO   Bulgaria;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   NCT03621280   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-004647-20-NL   Bulgaria;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-IT   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-004647-20-GR   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-ES   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-004647-20-BG   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-004647-20-HU   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2018   Phase 3   EUCTR2017-001219-35-PL   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-NL   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-HU   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-GR   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-FR   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-ES   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-DK   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-BG   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2017   Phase 3   NCT03277690   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2014   Phase 3   NCT01838551   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Netherlands;Poland;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Levoketozonazole
   CORTENDO AB
      2018   Phase 3   EUCTR2017-001219-35-IT   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
   Cortendo AB
      2020   Phase 3   EUCTR2017-004647-20-RO   Bulgaria;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-NL   Bulgaria;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-IT   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-004647-20-GR   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2017-004647-20-ES   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-004647-20-BG   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-004647-20-HU   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Turkey;United States
      2018   Phase 3   EUCTR2017-001219-35-PL   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-NL   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-HU   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-GR   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-FR   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-ES   Bulgaria;Canada;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-DK   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 3   EUCTR2017-001219-35-BG   Bulgaria;Denmark;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
Liqourice
   Umeå University
      2018   -   NCT04045015   Sweden
Liraglutide
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
Lmwh/rivaroxaban
   Huashan Hospital
      2020   -   NCT04486859   China
LU AG13909
   H. Lundbeck A/S
      2024   Phase 2   NCT06471829   France;Georgia;Hungary;Italy;Romania;Spain
Matyrapone
   S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano
      2013   -   EUCTR2013-002063-26-IT   Italy
Metarapone
   IRCCS Azienda Ospedaliero-Universitaria di Bologna
      2021   Phase 4   NCT06801249   Italy
Metformin
   Barts & The London NHS Trust
      2012   Phase 2/Phase 3   NCT01319994   United Kingdom
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
   Queen Mary University of London
      2010   Phase 2   EUCTR2008-005708-18-GB   United Kingdom
Methionine
   Hospices Civils de Lyon
      2017   -   NCT03346954   France
Metirapone
   AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
      2019   Phase 4   EUCTR2019-002008-41-IT   Italy
Metopirone 250 MG capsules
   Laboratoire HRA Pharma
      2016   Phase 4   EUCTR2014-000162-22-PL   Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
      2015   Phase 3   EUCTR2014-000162-22-ES   Belgium;Germany;Hungary;Italy;Poland;Spain;Sweden;Switzerland;United States
      2015   Phase 4   EUCTR2014-000162-22-DE   Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
      2015   Phase 4   EUCTR2014-000162-22-BE   Belgium;Germany;Hungary;Italy;Poland;Spain;Sweden;Switzerland;United States
Metopirone 250 MG capsules/ cormeto
   Laboratoire HRA Pharma
      2018   Phase 3   EUCTR2014-000162-22-RO   Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
Metopirone 250 MG capsules/cormeto
   Laboratoire HRA Pharma
      2015   Phase 4   EUCTR2014-000162-22-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;Sweden;Switzerland;United States
Metyrapone
   HRA Pharma
      2015   Phase 3   NCT02297945   Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
   Laboratoire HRA Pharma
      2018   Phase 3   EUCTR2014-000162-22-RO   Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
      2016   Phase 4   EUCTR2014-000162-22-PL   Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
      2015   Phase 4   EUCTR2014-000162-22-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;Sweden;Switzerland;United States
      2015   Phase 4   EUCTR2014-000162-22-HU   Belgium;Germany;Hungary;Italy;Poland;Spain
      2015   Phase 3   EUCTR2014-000162-22-ES   Belgium;Germany;Hungary;Italy;Poland;Spain;Sweden;Switzerland;United States
      2015   Phase 4   EUCTR2014-000162-22-DE   Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
      2015   Phase 4   EUCTR2014-000162-22-BE   Belgium;Germany;Hungary;Italy;Poland;Spain;Sweden;Switzerland;United States
   S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano
      2013   -   EUCTR2013-002063-26-IT   Italy
Mifedren
   Sheffield Teaching Hospitals NHS Foundation Trust
      2009   Phase 2   EUCTR2007-007604-15-GB   United Kingdom
Mifepristone
   Corcept Therapeutics
      2013   Phase 3   NCT01925092   United States
      2010   Phase 3   NCT01371565   United States
      2009   Phase 3   NCT00936741   United States
      2007   Phase 3   NCT00569582   United States
   HRA Pharma
      2007   Phase 2   NCT00422201   France;Germany;Italy;Netherlands;United Kingdom;United States
   Laboratoire HRA Pharma
      2007   -   EUCTR2006-004679-36-NL   France;Germany;Italy;Netherlands
      2007   -   EUCTR2006-004679-36-DE   France;Germany;Italy;Netherlands;United States
      2006   -   EUCTR2006-004679-36-FR   France;Germany;Italy;Netherlands
   Sheffield Teaching Hospitals NHS Foundation Trust
      2009   Phase 2   EUCTR2007-007604-15-GB   United Kingdom
Nevanimibe hydrochloride
   Millendo Therapeutics, Inc.
      2017   Phase 2   EUCTR2016-002240-17-GB   United Kingdom;United States
Nizoral
   ASSOCIAZIONE ITALIANA ENDOCRINOLOGIA-METABOLISMO-IPOFISI
      2006   -   EUCTR2006-005218-11-IT   Italy
   Erasmus MC
      2007   -   EUCTR2006-004080-55-NL   Netherlands
NON commercial
   Dipartimento di Medicina-DIMED, università di Padova
      2021   Phase 2   EUCTR2019-004019-29-IT   Italy
Obese
   University Hospital, Bordeaux
      2012   -   NCT02889224   France
Ocrh
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   -   NCT00001452   United States
      1982   -   NCT00001180   United States
Octreotide
   Erasmus MC
      2011   -   EUCTR2011-003264-77-NL   Netherlands
Orocal
   Pierre Fabre Médicament
      2008   Phase 3   EUCTR2008-002280-14-FR   France
Osilodrostat
      2014   Phase 3   JPRN-jRCT2080222646   Europe;Japan;North America
   Novartis Pharmaceuticals
      2016   Phase 3   NCT02697734   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2015   Phase 2   NCT02468193   Japan
      2014   Phase 3   NCT02180217   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
   RECORDATI GROUP
      2023   -   NCT05633953   France
      2022   -   NCT05382156   France;Germany;Italy;Netherlands;United States
      2018   Phase 2   NCT03606408   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Thailand;Turkey;United States
   Recordati Rare Diseases Japan K.K
      2018   Phase 4   JPRN-jRCT2080224109   Asia except Japan;Europe;Japan;North America;South America
   University of Michigan
      2024   -   NCT06430528   United States
Osilodrostat 10MG
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-002840-34-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A
      2018   Phase 2   EUCTR2017-002840-34-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-001522-25-ES   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-004092-23-ES   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
   Novartis Pharma AG
      2020   Phase 2   EUCTR2018-001522-25-IT   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-FR   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2014-004092-23-PT   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-PL   Belgium;Brazil;Canada;China;Costa Rica;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-GR   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-BE   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2015   Phase 3   EUCTR2013-004766-34-NL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-FR   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-AT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
   RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
      2019   Phase 2   EUCTR2018-001522-25-BE   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
   Recordati AG
      2023   Phase 2   EUCTR2018-001522-25-FR   Belgium;Bulgaria;France;Israel;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-SI   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-GB   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-BG   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-NL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2019   Phase 2   EUCTR2017-002840-34-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002840-34-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2018   Phase 2   EUCTR2017-002840-34-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      -   Phase 2   EUCTR2017-002840-34-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
Osilodrostat 1MG
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-002840-34-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A
      2018   Phase 2   EUCTR2017-002840-34-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-001522-25-ES   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-004092-23-ES   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
   Novartis Pharma AG
      2020   Phase 2   EUCTR2018-001522-25-IT   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-FR   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2014-004092-23-PT   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-PL   Belgium;Brazil;Canada;China;Costa Rica;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-GR   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-BE   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2015   Phase 3   EUCTR2013-004766-34-NL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-FR   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-AT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
   RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
      2019   Phase 2   EUCTR2018-001522-25-BE   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
   Recordati AG
      2023   Phase 2   EUCTR2018-001522-25-FR   Belgium;Bulgaria;France;Israel;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-SI   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-GB   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-BG   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-NL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2019   Phase 2   EUCTR2017-002840-34-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002840-34-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2018   Phase 2   EUCTR2017-002840-34-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      -   Phase 2   EUCTR2017-002840-34-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
Osilodrostat 20MG
   Novartis Farmacéutica, S.A.
      2016   Phase 3   EUCTR2014-004092-23-ES   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2014-004092-23-PT   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-PL   Belgium;Brazil;Canada;China;Costa Rica;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-GR   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-BE   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2015   Phase 3   EUCTR2013-004766-34-NL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-FR   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-AT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
Osilodrostat 5MG
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-002840-34-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A
      2018   Phase 2   EUCTR2017-002840-34-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-001522-25-ES   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-004092-23-ES   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
   Novartis Pharma AG
      2020   Phase 2   EUCTR2018-001522-25-IT   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-FR   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2014-004092-23-PT   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-PL   Belgium;Brazil;Canada;China;Costa Rica;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-GR   Belgium;Brazil;Denmark;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2014-004092-23-BE   Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United States
      2015   Phase 3   EUCTR2013-004766-34-NL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-FR   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004766-34-AT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
   RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
      2019   Phase 2   EUCTR2018-001522-25-BE   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
   Recordati AG
      2023   Phase 2   EUCTR2018-001522-25-FR   Belgium;Bulgaria;France;Israel;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-SI   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-GB   Belgium;Bulgaria;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001522-25-BG   Belgium;Bulgaria;France;Italy;Slovenia;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002840-34-NL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2019   Phase 2   EUCTR2017-002840-34-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Costa Rica;France;Germany;Greece;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002840-34-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      2018   Phase 2   EUCTR2017-002840-34-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
      -   Phase 2   EUCTR2017-002840-34-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Costa Rica;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Thailand;Turkey;United States
Ossein hydroxyapatite
   Pierre Fabre Médicament
      2008   Phase 3   EUCTR2008-002280-14-FR   France
Osteopor
   Pierre Fabre Médicament
      2008   Phase 3   EUCTR2008-002280-14-FR   France
Pasireotida 300
   NOVARTIS FARMACEUTICA S.A.
      2011   Phase 3   EUCTR2010-024165-44-ES   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
Pasireotida 600
   NOVARTIS FARMACEUTICA S.A.
      2011   Phase 3   EUCTR2010-024165-44-ES   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
Pasireotida 900
   NOVARTIS FARMACEUTICA S.A.
      2011   Phase 3   EUCTR2010-024165-44-ES   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
Pasireotide
   Erasmus MC
      2007   -   EUCTR2006-004080-55-NL   Netherlands
   NOVARTIS FARMA
      2011   Phase 3   EUCTR2009-011128-70-IT   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2006   -   EUCTR2006-004111-22-IT   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2004   -   EUCTR2004-002407-32-IT   Italy;United Kingdom
   Novartis Farmaceútica S.A.
      2007   -   EUCTR2006-004111-22-ES   Argentina;Belgium;Brazil;Canada;China;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Poland;Portugal;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2015   Phase 4   EUCTR2013-000267-84-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2011   Phase 3   EUCTR2009-011128-70-ES   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 4   EUCTR2013-000267-84-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2012   Phase 3   EUCTR2010-024165-44-NL   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
      2011   -   EUCTR2010-024165-44-GR   Czech Republic;Germany;Greece;Netherlands;Spain
      2011   Phase 3   EUCTR2010-024165-44-DE   Czech Republic;Germany;Greece;Netherlands;Spain
      2011   Phase 3   EUCTR2009-011128-70-GB   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Netherlands;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2008   -   EUCTR2006-004111-22-HU   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2008   Phase 3   EUCTR2006-004111-22-GB   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-PT   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-GR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FI   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-DK   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-DE   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-004111-22-BE   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
   Novartis Pharmaceuticals
      2006   Phase 3   NCT00434148   Argentina;Belgium;Brazil;Canada;China;Denmark;Finland;France;Germany;Greece;Israel;Italy;Mexico;Poland;Portugal;Spain;Turkey;United States
      2004   Phase 2   NCT00171951   France;Germany;Italy;United Kingdom;United States
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002407-32-GB   Italy;United Kingdom
Pasireotide 0.3MG
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
Pasireotide 0.6 MG/ML
   University of Palermo
      2013   Phase 4   NCT03080181   -
Pasireotide 0.6MG
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
Pasireotide 0.9 MG
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
Pasireotide 20MG
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Pasireotide 40MG
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Pasireotide 60MG
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Pasireotide diaspartate
   NOVARTIS FARMA S.p.A.
      2014   Phase 2   EUCTR2013-002170-49-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica , S.A.
      2013   Phase 2   EUCTR2013-002170-49-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2013-002170-49-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 2   EUCTR2013-002170-49-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2013   Phase 2   EUCTR2013-002170-49-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2013   Phase 2   EUCTR2013-002170-49-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2011   -   EUCTR2010-024165-44-CZ   Brazil;Czech Republic;Germany;Greece;Korea, Republic of;Netherlands;Romania;Russian Federation;Spain;Thailand;United States
Pasireotide LAR
   Novartis Pharma Services AG
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
      2011   Phase 3   NCT01374906   Argentina;Belgium;Brazil;Canada;China;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
   RECORDATI GROUP
      2013   Phase 4   NCT01794793   Argentina;Belgium;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;Thailand;Turkey;United States
Pasireotide pamoate
   NOVARTIS FARMA
      2013   Phase 4   EUCTR2013-000267-84-IT   Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Mexico;Poland;Portugal;Russian Federation;Spain;Thailand;United States
   Novartis Pharma Services AG
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2011   Phase 3   EUCTR2009-011128-70-PL   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-NL   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Netherlands;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-DE   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-BE   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
Pasireotide SUB-cutaneous
   Novartis Pharmaceuticals
      2011   Phase 3   NCT01582061   Brazil;Czech Republic;Czechia;Egypt;Germany;Greece;Korea, Republic of;Lebanon;Netherlands;Romania;Russian Federation;Spain;Thailand;United States
Pasireotide with or without cabergoline
   Novartis Pharmaceuticals
      2014   Phase 2   NCT01915303   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela
Pasireotode
   Novartis Pharma Services AG
      2007   -   EUCTR2006-004111-22-FR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
Pentetreotide
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1999   Phase 1/Phase 2   NCT00001849   United States
PHE
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002407-32-GB   Italy;United Kingdom
Phosphate
      2014   Phase 3   JPRN-jRCT2080222646   Europe;Japan;North America
   Recordati Rare Diseases Japan K.K
      2018   Phase 4   JPRN-jRCT2080224109   Asia except Japan;Europe;Japan;North America;South America
Pyridin
   CORCEPT THERAPEUTICS
      2019   Phase 3   EUCTR2018-003096-35-IT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
   Corcept Therapeutics Incorporated
      2022   Phase 2;Phase 3   EUCTR2018-001616-30-NL   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 3   EUCTR2018-003096-35-RO   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 2;Phase 3   EUCTR2018-001616-30-RO   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-ES   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-DE   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-BG   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-PL   Austria;Bulgaria;Canada;Colombia;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-NL   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-ES   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-DE   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-BG   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-AT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 2   EUCTR2018-001616-30-HU   Bulgaria;Germany;Hungary;Italy;Netherlands;Romania;Spain;United States
R-roscovitine
   Shlomo Melmed, MD
      2014   Phase 2   NCT02160730   United States
Relacorilant
   CORCEPT THERAPEUTICS
      2019   Phase 3   EUCTR2018-003096-35-IT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 2   EUCTR2018-001616-30-IT   Bulgaria;Germany;Hungary;Italy;Netherlands;Romania;Spain;United States
   Corcept Therapeutics
      2022   Phase 1   NCT05347979   United States
      2018   Phase 3   NCT03697109   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 2   NCT03604198   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
   Corcept Therapeutics Incorporated
      2022   Phase 2;Phase 3   EUCTR2018-001616-30-NL   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 3   EUCTR2018-003096-35-RO   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2021   Phase 2;Phase 3   EUCTR2018-001616-30-RO   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-ES   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2018-001616-30-BG   Austria;Bulgaria;Canada;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-PL   Austria;Bulgaria;Canada;Colombia;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-NL   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-ES   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-DE   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-BG   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2019   Phase 3   EUCTR2018-003096-35-AT   Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain;United States
      2018   Phase 2   EUCTR2018-001616-30-HU   Bulgaria;Germany;Hungary;Italy;Netherlands;Romania;Spain;United States
      2016   Phase 2   EUCTR2016-000899-23-GB   Hungary;Netherlands;United Kingdom;United States
Rosiglitazone maleate
   Jonsson Comprehensive Cancer Center
      2007   Phase 2   NCT00612066   United States
Routine MRI scan
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 2   NCT02019706   United States
RVG 08938
   Erasmus MC
      2011   -   EUCTR2011-003264-77-NL   Netherlands
RVG 15375
   Erasmus MC
      2011   -   EUCTR2011-003264-77-NL   Netherlands
RVG 18236
   Erasmus MC
      2011   -   EUCTR2011-003264-77-NL   Netherlands
Saliva swab
   Centre Hospitalier Universitaire de Nimes
      2019   -   NCT03974789   France
Seliciclib
   Cedars-Sinai Medical Center
      2018   Phase 2   NCT03774446   United States
Signifor
   NOVARTIS FARMA
      2013   Phase 4   EUCTR2013-000267-84-IT   Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Mexico;Poland;Portugal;Russian Federation;Spain;Thailand;United States
   NOVARTIS FARMA S.p.A.
      2014   Phase 2   EUCTR2013-002170-49-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica , S.A.
      2013   Phase 2   EUCTR2013-002170-49-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica, S.A.
      2015   Phase 4   EUCTR2013-000267-84-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
   Novartis Pharma Services AG
      2016   Phase 4   EUCTR2013-000267-84-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2015   Phase 2   EUCTR2013-002170-49-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 2   EUCTR2013-002170-49-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2013   Phase 2   EUCTR2013-002170-49-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2011   Phase 3   EUCTR2010-024165-44-DE   Czech Republic;Germany;Greece;Netherlands;Spain
      2011   -   EUCTR2010-024165-44-CZ   Brazil;Czech Republic;Germany;Greece;Korea, Republic of;Netherlands;Romania;Russian Federation;Spain;Thailand;United States
      2011   Phase 3   EUCTR2009-011128-70-PL   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-NL   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Netherlands;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-BE   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Silycus
   ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A.
      2021   Phase 2   EUCTR2020-005605-93-IT   Italy
Sitagliptin
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
SOM230
   Erasmus MC
      2007   -   EUCTR2006-004080-55-NL   Netherlands
   NOVARTIS FARMA
      2013   Phase 4   EUCTR2013-000267-84-IT   Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Mexico;Poland;Portugal;Russian Federation;Spain;Thailand;United States
      2011   Phase 3   EUCTR2009-011128-70-IT   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
   NOVARTIS FARMA S.p.A.
      2014   Phase 2   EUCTR2013-002170-49-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   NOVARTIS FARMACEUTICA S.A.
      2011   Phase 3   EUCTR2010-024165-44-ES   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
   Novartis Farmaceútica S.A.
      2007   -   EUCTR2006-004111-22-ES   Argentina;Belgium;Brazil;Canada;China;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Poland;Portugal;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica , S.A.
      2013   Phase 2   EUCTR2013-002170-49-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica, S.A.
      2015   Phase 4   EUCTR2013-000267-84-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2011   Phase 3   EUCTR2009-011128-70-ES   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 4   EUCTR2013-000267-84-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2015   Phase 2   EUCTR2013-002170-49-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2014   Phase 2   EUCTR2013-002170-49-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2013   Phase 2   EUCTR2013-002170-49-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United Kingdom;United States;Venezuela, Bolivarian Republic of
      2013   Phase 2   EUCTR2013-002170-49-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;United States;Venezuela, Bolivarian Republic of
      2012   Phase 3   EUCTR2010-024165-44-NL   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
      2011   -   EUCTR2010-024165-44-GR   Czech Republic;Germany;Greece;Netherlands;Spain
      2011   -   EUCTR2010-024165-44-CZ   Brazil;Czech Republic;Germany;Greece;Korea, Republic of;Netherlands;Romania;Russian Federation;Spain;Thailand;United States
      2011   Phase 3   EUCTR2009-011128-70-PL   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-NL   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Netherlands;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-GB   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Netherlands;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-DE   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-011128-70-BE   Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Japan;Peru;Poland;Spain;Thailand;Turkey;United Kingdom;United States
      2008   -   EUCTR2006-004111-22-HU   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2008   Phase 3   EUCTR2006-004111-22-GB   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-PT   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-GR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FI   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-DK   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-DE   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-004111-22-BE   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
   Novartis Pharmaceuticals
      2004   Phase 2   NCT00088608   France;Italy;United Kingdom;United States
   RECORDATI GROUP
      2013   -   NCT02310269   Canada;Colombia;Denmark;France;Germany;Israel;Italy;Lebanon;Netherlands;Romania;Sweden;United Kingdom;United States
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
SOM230 300µG
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2010-024165-44-DE   Czech Republic;Germany;Greece;Netherlands;Spain
SOM230 600µG
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2010-024165-44-DE   Czech Republic;Germany;Greece;Netherlands;Spain
SOM230 900µG
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2010-024165-44-DE   Czech Republic;Germany;Greece;Netherlands;Spain
SOM230 LAR
   Novartis Pharma Services AG
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230 LAR 10 MG
   Novartis Pharmaceuticals
      2011   Phase 3   NCT01374906   Argentina;Belgium;Brazil;Canada;China;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
SOM230 LAR 30 MG
   Novartis Pharmaceuticals
      2011   Phase 3   NCT01374906   Argentina;Belgium;Brazil;Canada;China;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Russian Federation;Spain;Thailand;Turkey;United Kingdom;United States
SOM230 LAR, 20 MG
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230, 300micrograms
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230, 600 micrograms
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230, 900 micrograms
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230B
   Erasmus MC
      2007   -   EUCTR2006-004080-55-NL   Netherlands
   NOVARTIS FARMA
      2006   -   EUCTR2006-004111-22-IT   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2004   -   EUCTR2004-002407-32-IT   Italy;United Kingdom
   NOVARTIS FARMACEUTICA S.A.
      2011   Phase 3   EUCTR2010-024165-44-ES   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
   Novartis Farmaceútica S.A.
      2007   -   EUCTR2006-004111-22-ES   Argentina;Belgium;Brazil;Canada;China;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Poland;Portugal;Spain;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2012   Phase 3   EUCTR2010-024165-44-NL   Argentina;Brazil;Czech Republic;Egypt;Germany;Greece;Hungary;Korea, Republic of;Netherlands;Romania;Spain;Thailand
      2011   -   EUCTR2010-024165-44-GR   Czech Republic;Germany;Greece;Netherlands;Spain
      2011   Phase 3   EUCTR2010-024165-44-DE   Czech Republic;Germany;Greece;Netherlands;Spain
      2011   -   EUCTR2010-024165-44-CZ   Brazil;Czech Republic;Germany;Greece;Korea, Republic of;Netherlands;Romania;Russian Federation;Spain;Thailand;United States
      2008   -   EUCTR2006-004111-22-HU   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2008   Phase 3   EUCTR2006-004111-22-GB   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-PT   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-GR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FR   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-004111-22-FI   Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   -   EUCTR2006-004111-22-DK   Belgium;Denmark;Finland;Germany;Greece;Hungary;Italy;Portugal;United Kingdom
      2007   Phase 3   EUCTR2006-004111-22-BE   Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002407-32-GB   Italy;United Kingdom
SOM230C
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
Somatropin
   Amar Agha, Beaumont Hospital
      2009   Phase 4   EUCTR2009-010918-30-IE   Ireland
SPI-62
   Sparrow Pharmaceuticals
      2022   Phase 2   NCT05307328   Bulgaria;Romania;United States
   Sparrow Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-006184-19-RO   Bulgaria;Romania;United States
      2022   Phase 2   EUCTR2021-006184-19-BG   Bulgaria;Romania;United States
SPI-62 dose
   Sparrow Pharmaceuticals
      2023   Phase 2   NCT05436639   Bulgaria;France;Germany;Italy;Romania;United Kingdom;United States
Standardized antihypertensive therapy
   IRCCS Azienda Ospedaliero-Universitaria di Bologna
      2021   Phase 4   NCT06801249   Italy
Tadalafil
   Andrea M. Isidori
      2016   Phase 2   NCT02611258   Italy
   UMBERTO I - POLICLINICO DI ROMA
      2016   Phase 2   EUCTR2015-004497-15-IT   Italy
Tretinoin
   ISTITUTO AUXOLOGICO ITALIANO
      2008   -   EUCTR2008-006379-65-IT   Italy
Tretinoina
   Dipartimento di Medicina-DIMED, università di Padova
      2021   Phase 2   EUCTR2019-004019-29-IT   Italy
TRP
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002407-32-GB   Italy;United Kingdom
TYR
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002407-32-GB   Italy;United Kingdom
Valsartan
   Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus
      2009   -   JPRN-UMIN000002925   Japan
Vesanoid
   Dipartimento di Medicina-DIMED, università di Padova
      2021   Phase 2   EUCTR2019-004019-29-IT   Italy
Vorinostat
   National Institute of Neurological Disorders and Stroke (NINDS)
      2025   Phase 2   NCT04339751   United States
Zoledronic acid
   Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2024   -   ChiCTR2400091528   China
Zytiga - 250 MG - compressa - USO orale - flacone 120 compresse
   AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
      2016   Phase 2   EUCTR2016-000945-29-IT   Italy